Confirm histological grade
Confirm histological diagnosis and grade, which is the main determinant of prognosis.
Specialized Unit
Appendicular Carcinomatosis and Pseudomyxoma Peritonei
At Quenet-Torrent Institute, we specialize in treating appendicular peritoneal carcinomatosis and pseudomyxoma peritonei — conditions with among the best prognoses of all peritoneal malignancies when managed in a specialized center.
CONTACT SPECIALISTNeed to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon
-
EXTENSIVE EXPERIENCE +20,000 surgeries performed
-
LATEST TECHNOLOGY in surgical strategy
-
PERSONALIZED CARE First contact within 24/48h
Schedule your consultation with a specialist
What is appendicular carcinomatosis?
Appendicular carcinomatosis refers to peritoneal dissemination originating from appendicular tumors. The most notable form is pseudomyxoma peritonei, a rare condition characterized by progressive accumulation of mucinous material in the abdominal cavity — colloquially known as "jelly belly".
These tumors span a histological spectrum from low-grade mucinous neoplasms (LAMN) to mucinous adenocarcinoma. Among all peritoneal malignancies, this group has the most favorable prognosis when treated with complete cytoreduction and HIPEC in specialized centers.
With complete resection (CC0/CC1), 10-year survival can exceed 70% in low-grade tumors, and 5-year survival over 80% in selected cases.
Why request a second opinion for appendicular carcinomatosis?
This rare condition requires management in specialized centers with extensive experience.
Evaluate resectability
Assess whether complete cytoreduction is achievable based on disease extent.
Optimal timing
Determine the best time for surgery — particularly relevant in slow-growing low-grade disease.
Specialized center
Ensure you are treated at a center with documented experience in these rare tumors.
The surgeon's experience is the most important prognostic factor in pseudomyxoma peritonei.
How do we treat appendicular carcinomatosis?
Surgical treatment combined with HIPEC is the standard of care and the foundation of potentially curative management.
Complete cytoreductive surgery
Removal of all visible mucinous disease and affected peritoneal surfaces — the most critical factor for cure.
HIPEC
Hyperthermic intraperitoneal chemotherapy to destroy microscopic residual cells after cytoreduction.
Multivisceral resections
Removal of affected organs when necessary: omentum, spleen, gallbladder, ovaries, portions of bowel.
Iterative surgery
Repeat interventions for recurrences in selected patients — particularly effective in low-grade disease.
The goal is complete cytoreduction (CC-0/CC-1) to maximize long-term survival.
Our Technology
Technology for treating appendicular carcinomatosis
Specialized technology is essential in these complex and often lengthy surgeries.
Automated HIPEC equipment
Precise thermal and flow control for optimal intraperitoneal perfusion.
CT and MRI imaging
Detailed preoperative evaluation of disease distribution and extent.
Tumor markers (CEA, CA 19-9)
Serial monitoring for disease follow-up and early detection of recurrence.
Expert pathology review
Specialist pathologists for accurate histological grading — critical for prognosis.
WHY CHOOSE US?
Reference center for pseudomyxoma peritonei
Quenet-Torrent Institute is a reference center for these rare appendicular conditions with extensive accumulated experience.
Experience in Complex Cases
We specialize in treating advanced and metastatic cancer, using innovative techniques that other teams do not offer.
Comprehensive Multidisciplinary Approach
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
Research and Innovation
We stay up to date with the latest scientific advances, allowing us to apply innovative treatments with better results.
State-of-the-Art Technology
We have facilities equipped with the most current medical technology, allowing us to perform high-precision procedures with less impact on the body.
Personalized and Close Care
We care about each patient as a person. We listen, support, and guide every step of the way.
Our Team
Appendicular carcinomatosis specialists
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Dr. François Quenet
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Dr. Juan José Torrent
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
Frequently asked questions about appendicular carcinomatosis
Answers to the most common questions about diagnosis, treatment, and prognosis.
What is pseudomyxoma peritonei?
A syndrome characterized by progressive accumulation of mucinous material in the abdominal cavity, usually originating from an appendicular mucinous tumor.
Is pseudomyxoma peritonei cancer?
It depends on the type. Low-grade LAMN is considered borderline; mucinous adenocarcinoma is cancer. In both cases, the approach is similar: complete cytoreduction with.
What is the prognosis of pseudomyxoma peritonei?
Excellent when treated in specialized centers. With complete cytoreduction and HIPEC, 10-year survival can exceed 70% in low-grade tumors Outcomes depend on histology, PCI score, and completeness of cytoreduction.
How long does surgery take?
Cytoreductive surgery with HIPEC can last 8-14 hours depending on disease extent, with continuous adjustment based on intraoperative findings of the case.
What if the disease recurs?
Repeat surgeries are possible and can be effective, particularly in low-grade disease where long-term control is achievable over multiple interventions.
Where can I receive this treatment safely?
In specialized centers with extensive experience in pseudomyxoma and appendicular tumors, like Quenet-Torrent Institute Chemotherapy complements surgery to optimise overall oncological control.
Easy Contact
Need to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon.